Pfizer wins TRO against ex-marketing manager accused of stealing launch plans

Pfizer has sued a former global marketing manager for allegedly copying thousands of files that contain proprietary info, including "specific product launch roadmaps."

Pfizer claims one of its former global marketing managers tried to make off with launch secrets—and now, it’s working to stop her in her tracks.

The pharma giant has won a temporary restraining order (TRO) against Aimee de Blasis Amman, who it says is holding on to a USB drive full of files and 42 emails she forwarded to her personal account before resigning in January. The messages and files contain “proprietary, confidential and trade secret information,” the company claims.

The order, issued in a U.S. District Court in Pennsylvania, now prohibits Amman from using, transferring and destroying any of Pfizer’s confidential info.


The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

The TRO came just days after the pharma giant sued Amman, claiming the emails she sent to herself included sensitive info on Pfizer’s “strategic planning, short- and long-term operating plans, and specific product launch roadmaps." And that was information the judge in the case agreed could cause “severe and irreparable harm” if it were to fall into the wrong hands.

Amman secretly copied 600 Pfizer files—some of which were folders that contained a total of 6,000 documents, the legal complaint says. The former marketing manager made off with those files in an "unencrypted removable usb external hard drive device" during her last weeks at Pfizer, "including the days before she resigned," the lawsuit says.

Pfizer, of course, has plenty of launch plans it would like to keep to itself. The company is preparing to roll out Eucrisa, the recently approved, wannabe eczema blockbuster from new buy Anacor. And it has other competitive rollouts underway; the drugmaker’s hot new breast cancer seller Ibrance is about to gain new competition from Novartis, whose LEE011 could rack up $1.6 billion by 2022, EP Vantage predicts.  


Suggested Articles

Novartis is doing more portfolio pruning, offloading three endocrine drugs to Recordati.

Turns out, the FDA’s March rejection of Sanofi's Zynquista was just a preview of what would come for the SGLT class in Type 1 diabetes.

Indoco Remedies is not just getting the once over by the FDA but the twice-over as inspectors work through its plants and citations rain down.